Paolo Calabrò: Lower LDL-C Variability With PCSK9 Inhibitors and Inclisira
Paolo Calabrò, Director of the Cardiovascular Department at S. Anna and S. Sebastiano Hospital, shared on LinkedIn:
”Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy.”
Title: Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy
Authors: Arturo Cesaro, Vincenzo Acerbo, Francesco Scialla, Andrea Zito, Gennaro Porcelli, Domenico Panico, Giovanni Argenziano, Demetrio Iaria, Maria Grazia Monaco, Vincenzo De Sio, Felice Gragnano, Michele Golino, Massimiliano Ruscica, Stefano Carugo, Alberto Corsini, Paolo Calabrò
Read the full article here.
Stay updated with Hemostasis Today.
-
Jun 15, 2026, 18:24Celebrating Emna Gouider’s Renewed Leadership at WFH Congress 2026 – WFH
-
Jun 15, 2026, 18:14Anastasia Conti: Connecting Celebrating and Advancing Hematology at EHA 2026
-
Jun 15, 2026, 18:01Eric Mwenda: Honoring Blood Donors and Partnerships in Tanzania
-
Jun 15, 2026, 17:37Vincent Elsey: The Ethereal Anatomy of a Broken Vessel
-
Jun 15, 2026, 17:20Megan Adediran: Small Act, Massive Impact – Celebrating Blood Donor Day
-
Jun 15, 2026, 16:52Alejandro González Veliz: A Modern Approach to Anticoagulant Management
-
Jun 15, 2026, 16:20New Therapeutic Strategies Targeting Iron Metabolism
-
Jun 15, 2026, 15:43Antonio Paul: Donor Safety Is More Than a Sterile Needle
-
Jun 15, 2026, 15:36Alejandro González Veliz: A Coronary Calcium Score of Zero Doesn’t Always Mean Zero Risk